Breadcrumb

null The Pfizer Investigator Training Program comes to the RI-MUHC!

Clinical research educational training program benefits researchers, staff and students at the inaugural event

Jan. 29, 2020

Source: RI-MUHC. On January 28 the Research Institute of the McGill University Health Centre (RI-MUHC) teamed up with Pfizer Canada to offer an educational workshop to 120 members of the research community. Specifically designed by Pfizer for clinical trial investigators and their study staff, the Pfizer Investigator Training Program (ITP) supports researchers interested in improving the many skills required for the planning, conduct and reporting of clinical trials.

Covering the entire trial process from planning through close-out activities, the ITP workshop offered practical recommendations for increasing the efficacy of clinical trial conduct at investigative sites. It also provided a forum in which everyone involved in clinical trials could share their experiences and receive practical advice.

“It’s very effective to bring together researchers and clinicians for this kind of training event,” said Virginia Lee, a scientist in the Cancer Research Program at the RI-MUHC and assistant professor in the Ingram School of Nursing, Faculty of Medicine, at M cGill University. “The information being presented is really current and relevant,” added participant Marie-Claude Joncas, a supervisor in the Centre for Innovative Medicine (CIM) at the RI-MUHC.

Left to right: Darren Cowan (Executive Director, Global Product Development, Pfizer), Virginia Lee, PhD (Scientist, Cancer Research Program, Research Institute of the MUHC), and Sally Robidoux (Site Relationship Partner, Pfizer)
Left to right: Darren Cowan (Executive Director, Global Product Development, Pfizer), Virginia Lee, PhD (Scientist, Cancer Research Program, Research Institute of the MUHC), and Sally Robidoux (Site Relationship Partner, Pfizer)

The training benefits researchers and their trainees as well as the drug development industry. Pfizer is always looking to expand its pool of qualified clinical trial investigators and to improve the overall quality of clinical trials, and workshops like the ITP can help with these objectives.

“I am really proud to be partnering with the RI-MUHC to bring clinical trials to Canada,” said Claudia de Paola, a site relationship partner at Pfizer Canada. “We are working together to streamline the start-up activities of our clinical trials and enhance the overall quality of research, which in turn will help bring innovative medicines to Canadian patients.”

Participants in the Pfizer Investigator Training Program (ITP) in the Cruess Amphitheatre, Research Institute of the MUHC (January 28, 2020)
Participants in the Pfizer Investigator Training Program (ITP) in the Cruess Amphitheatre, Research Institute of the MUHC (January 28, 2020)
Participants and organizers, Pfizer Investigator Training Program (ITP) in the Cruess Amphitheatre, Research Institute of the MUHC (January 28, 2020)
Participants and organizers, Pfizer Investigator Training Program (ITP) in the Cruess Amphitheatre, Research Institute of the MUHC (January 28, 2020)
Participants in the Pfizer Investigator Training Program (ITP) in the Cruess Amphitheatre, Research Institute of the MUHC (January 28, 2020)
Participants in the Pfizer Investigator Training Program (ITP) in the Cruess Amphitheatre, Research Institute of the MUHC (January 28, 2020)
Organizers of the Pfizer Investigator Training Program (ITP) in the Cruess Amphitheatre, Research Institute of the MUHC (January 28, 2020)
Organizers of the Pfizer Investigator Training Program (ITP) in the Cruess Amphitheatre, Research Institute of the MUHC (January 28, 2020)

About the Research Institute of the McGill University Health Centre

With over 1,500 clinical studies underway and more than 135,000 participants, the Research Institute of the McGill University Health Centre (RI-MUHC) is one of the largest and most modern research centres in the field of biomedical sciences and health care in North America.

The RI-MUHC is the research arm of the McGill University Health Centre (MUHC), a university hospital complex serving six hospitals in Montreal (Quebec, Canada), and is affiliated with the McGill University Faculty of Medicine.

The RI-MUHC is home to the McConnell Centre for Innovative Medicine (CIM), a unit specializing in the conduct and management of phase l to lV clinical studies. The CIM provides comprehensive clinical research services following the highest quality standards, in a state-of-the-art environment dedicated exclusively to clinical research. Watch the video.